Agonist activity of LSD and lisuride at cloned 5HT(2A) and 5HT(2C) receptors

Psychopharmacology

Volumn 136, Issue 4, 1998, Pages 409-414

  Egan, Christina T ^a   Herrick Davis, Katharine ^a   Miller, Keith ^b   Glennon, Richard A ^c   Teitler, Milt ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1 (2,5 Dimethoxy 4 methylphenyl)2 amino propane (DOM); 5 Hydroxytryptamine (5HT); 5HT(2A) receptor; 5HT(2C) receptor; Hallucinogenic drug; Inositol phosphate (IP) production; Lisuride; Lysergic acid diethylamide (LSD); N,N Dimethyltryptamine (DMT)

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; INOSITOL PHOSPHATE; LISURIDE; LYSERGIDE; MIANSERIN; N,N DIMETHYLTRYPTAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HALLUCINATION; NONHUMAN; PARKINSON DISEASE; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SEROTONINERGIC SYSTEM;

EID: 0031970639     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050585     Document Type: Article

References (37)

1. Adams LM, Geyer MA (1985) Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide. Pharmacol Biochem Behav 23:461-468
2. 1C receptors in rat brain. J Pharmacol Exp Ther 255:843-857
3. 2C receptors reveal novel inverse agonist activity of receptor Iigands. J Biol Chem 269:11687-11690
4. Berridge MJ, Downes PC, Hanley MR (1982) Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 206:587-595
5. 1C receptor agonist. J Pharmacol Exp Ther 258:891-896
6. 2 binding site in rat cerebral cortex but not subcortical regions. J Pharmacol ExpTher 234:95 203
7. Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR (1986) A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc Natl Acad Sci USA 83: 4086-4088
8. Critchley P, Grandas Perez F, Quinn NP (1988) Continuous subcutaneous lisuride infusions in parkinson' disease. J Neural Transm 27:55-60
9. 1C mediated phenomenon. Pharmacol Biochem Behav 48:383-396
10. Fernandez Pardal M, Micheli F, Gatto M, Perez Y, Gonzalez N (1988) Treatment of parkinson's disease with subcutaneous lisuride infusions. J Neural Transm 27:75-84
11. Gershanik OS, Scipioni O, Garcia S (1988) Lisuride infusion pump in Parkinson's disease. A report of two cases. J Neural Transm 27:85-90
12. Geyer MA, Krebs KM (1994) Serotonin receptor involvement in an animal model of the acute effects of hallucinogens. NIDA Res Monogr 146:124-156
13. Glennon RA, Hauck AE (1985) Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav 23: 937-941
14. 2 involvement in the mechanisms of action of hallucinogenic agents. Life Sci 35:2505-2511
15. 2 receptors in the rat medial prefrontal cortex. Behavioral studies. Soc Neurosci Abstr 18:P1380
16. Holohean AM, White FJ, Appel JB(1992) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81:595-602
17. LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB (1982) Lisuride versus bromocriptine treatment in parkinson diseases: a double-blind study. Neurology 32:69-72
18. 2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 278:1373-1382
19. Marini JL, Jacobs BL, Sheard MH, Trulson ME (1981) Activity of a nonhallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology 73:328-331
20. McCall RB, Aghajanian GK (1980) Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus. Life Sci 26:1149-1156
21. Nielsen EB (1985) Discriminative stimulus properties of lysergic acid diethylamide in the monkey. J Pharmacol Exp Ther 234:244-249
22. Nutt JG, Hammerstad JP, Carter JH, deGarmo PL (1985) Lisuride treatment of focal dystonias, Neurology 35:1242-1243
23. Obeso JA, Luquin MR, Vaamonde J, Martinez Lage JM (1988) Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson's diseases. J Neural Transm 27:17-25
24. O'Brien CP (1996) Drug addiction and drug abuse. In: Hardman JG, Limbard LE (eds) Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 557-577
25. 2 antagonists. Brain Res 385:395-400
26. Roth BL, Craigo SC, Salmon Choudhary M, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
27. 1C receptor activation by hallucinogenic drugs. Psychopharmacology 105:340-346
28. Sanders-Bush E, Burris KD, Knoth K (1991) Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924-928
29. Teitler M, Lyon RA, Herrick-Davis K, Glennon RA (1987) Selectivity of serotinergic drugs for multiple serotonin receptors. Bio Pharm 36:3265-3271
30. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213-216
31. 2 receptor subtypes. Mol Pharmacol 38:594-598
32. Todes CJ (1986) At the receiving end of the lisuride pump. Lancet 2:36-37
33. Vaamonde J, Luquin MR, Obeso JA (1991) Subcutaneous leisured infusion in Parkinson's disease. Brain 114:601-614
34. 2F receptor. Mol Pharmacol 43:419-426
35. White FJ (1986) Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions. Pharmacol Biochem Behav 24:365-379
36. White FJ, Appel JB (1982) Lysergic acid diethylamide and lisuride: differentiation of their neuropharmacological actions. Sciences 216:535-537
37. Winter JC (1994) The stimulus effects of serotonergic hallucinogens in animals. In: Lin GC, Glennon RA (eds) Hallucinogens, an update. NIDA Research Monograph 146, Washington, DC, pp 157-182